Comparison of Endostar continuous versus intermittent intravenous infusion in combination with first‐line chemotherapy in patients with advanced non‐small cell lung cancer

BACKGROUND: Intravenous infusion of Endostar for three to four hours per day for 14 days reduces patient compliance and affects quality of life. Continuous intravenous infusion (CI) represents a novel method of administration; however, it is unclear whether it is effective and safe when compared to...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Yuan, Nie, Ligong, Liu, Ying, Jin, Zhe, Wang, Xi, Hu, Zhanwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6610280/
https://www.ncbi.nlm.nih.gov/pubmed/31161695
http://dx.doi.org/10.1111/1759-7714.13106

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6610280/
https://www.ncbi.nlm.nih.gov/pubmed/31161695
http://dx.doi.org/10.1111/1759-7714.13106

Ejemplares similares